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OBJECTIVES: To evaluate health care costs following acute coronary syndromes 
(ACS) in patients with/without recurrent cardiovascular events (CVEs). 
METHODS: Patients with ≥1 ICD-9 CM codes for acute myocardial infarction 
(410.xx) or unstable angina (411.1x) during ACS hospitalization were identified 
from the HealthCore Integrated Research Database January 1, 2006 to September 
30, 2011 (index event date defined as first ACS hospitalization date). Patients 
with <12 months pre/post-index plan eligibility or <18 years old were excluded. 
Recurrent CVEs were defined as myocardial infarction, non-fatal stroke or 
coronary heart disease-related mortality. Total and CV-related hospitalization 
costs following index ACS were evaluated in patients with/without recurrent 
CVEs, adjusting for demographic characteristics, comorbidities, treatment 
utilization and index ACS characteristics. RESULTS: Of 140,903 US patients, 22.0% 
had ≥1 subsequent CVE during follow-up. Patients with versus without recurrent 
CVEs were older - and had more comorbidities. Mean (median) follow-up was 2.0 
(1.6) and 1.9 (1.5) years in patients with and without recurrent CVEs, respectively. 
Mean (median) length of stay for index ACS hospitalization was longer in 
patients with versus without recurrent CVEs. Mean (median) 1-year post-index 
total and CV-related cost were higher in patients with versus without recurrence 
($41,478 [$17,474] and $34,094 [$10,057] versus $30,608 [$17,241] and $23,613 
[$10,336]; p<0.001). Inpatient hospitalization costs were the major driver of total 
expenditures, comprising 76% and 72% of total costs in patients with versus 
without recurrence, respectively. Mean 2- and 3-year post-index total and CV-
related costs were also significantly higher in patients with recurrent CVEs (2-
year: $27,746 and $20,572 vs. $18,707 and $12,794; 3-year: $21,880 and $15,260 vs. 
$14,438 and $9,049; p<0.001). CONCLUSIONS: Following ACS hospitalization, 
patients with recurrent CVEs incurred higher 1-, 2- and 3-year post-index event 
costs compared those without recurrence, underscoring the need to focus on the 
prevention of subsequent adverse CVEs following ACS to improve patient 
outcomes and reduce total health care cost.  
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OBJECTIVES: An increasing proportion of coronary artery bypass grafting (CABG) 
surgery is performed with concomitant valve repair or replacement surgery, and 
complications related to these procedures can have significant impact on 
patients and health care systems. This study quantifies the incidence and 
clinical and economic burden of complications associated with CABG, valve and 
combined (CABG and valve) surgery in the US. METHODS: Premier Perspective 
database was used to identify patients having CABG and/or valve surgery 
between Jan 2008 to Dec 2011. The study complications were postoperative 
infection, septicemia, postoperative stroke, postoperative adult respiratory 
distress syndrome, new-onset hemodialysis, reoperation, respiratory 
complication, cardiac complication, and hemorrhage. Both surgeries and 
complications were identified by ICD-9 codes. This study investigated (1) overall 
incidence rate of any study complication, (2) differences in length of stay (LOS), 
and (3) total inpatient costs for patients with and without complications during 
index and readmission within 30 days across three procedures. For multivariate 
adjustments, Gamma-distributed generalized linear model (GLM) and Poisson-
distributed GLM models were used. RESULTS: Of 100,601 patients who 
underwent CABG alone, 31,903 (31.7%) had any study complications during their 
index or readmitted stay. Patients with valve alone or combined surgery had 
higher incidence of complications: 38.2% and 47.3% (p<0.01 for both), 
respectively. Complications in CABG incurred additional average LOS of 4.8 days 
(p<0.01) and additional average hospital cost of $14,699 (p<0.01) over CABG 
patients not experiencing complications, while complications in valve alone and 
combined surgery incurred an additional 6.8 days, $23,464 and 6.7 days, $24,985 
respectively. CONCLUSIONS: Results showed complications in CABG and/or 
valve surgery increase clinical and economic burden by 0.41 to 0.60 times in 
terms of additional LOS and hospital costs. The burden increases significantly 
when a patient has combined procedures. The results highlight the potential 
opportunity for cost reduction by preventing the complications associated with 
CABG and/or valve surgeries.  
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OBJECTIVES: Cost of illness in ischemic stroke has historically been reported as 
direct total health care cost, not compared to an equally ill, non-stroke, control 
group. This methodology likely overestimates cost and may affect national 
burden of illness estimates and cost effectiveness comparisons. The magnitude 
of the over-estimation is not known. The objective of this study is to estimate 
the 1-year marginal cost of ischemic stroke in SC Medicare beneficiaries and 
examine the impact of total versus marginal cost reporting on overall US stroke 
cost estimates and on the distribution of expenditures of inpatient care and 
rehabilitation. METHODS: Cost of illness was estimated from a Medicare cost 
perspective for ischemic stroke in South Carolina. Stroke patients were matched 
1:2 to non-stroke beneficiaries using nearest-neighbor propensity score 
matching. Standard Medicare analytic files for all beneficiaries in SC in 2004 and 
2005 were summed for the year following their index ischemic stroke or to death. 
The total study sample size was 8928. RESULTS: The use of a marginal costing 
approach produced lower estimates than the average total costing method. The 
2004 marginal costs of stroke were $26.9 million, while the average cost estimate 
was $81.3 million, a difference of $54.4 million. Average total cost includes 
expenditures for comorbid conditions which are common in patients with 
stroke. Cost of stroke for the US in 2012 would be overestimated by $4.89 billion 
if this difference is generalized to national estimates. Furthermore, the 
proportion of stroke costs attributable to rehabilitation services would change 
from 13.7% based on mean cost, to 29.3% using marginal estimates. 
CONCLUSIONS: Using a marginal costing approach to estimate health care costs 
for conditions common in patients with a high prevalence of comorbid 
conditions is essential for accurate estimation of burden of illness, as well as 
estimating in-hospital and follow-up cost distributions correctly.  
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OBJECTIVES: To estimate the costs-of-disease and direct cost components of 
thromboembolic complications associated with AF and the side-effects related 
with anticoagulant treatment, in Turkish setting. METHODS: A panel consisting 
of experts on cardiology, hematology, pulmonology and neurology, held a 
meeting to discuss the disease management processes of stroke, SE, IC bleeding 
and EC bleeding. They reviewed the global and local literature and guidelines, 
and also they discussed the spectrum of local clinical practices that are 
performed frequently. All cost components, including medications, surgical 
treatment, hospitalization, out-patient follow-up procedures and rehabilitation 
services were reviewed. September 2012 local prices for medications and 
procedures were used as sources. Mid-2012 USD currency rate was used. 
RESULTS: The cost of SE was estimated as 431 USD/event (70% non-
pharmacologic treatment cost). The cost of acute management of stroke was 
calculated as 2,517 USD, of which 76% was caused by hospital stay. The annual 
cost of follow-up of stroke patients was 799 USD/year. The source of almost half 
(48%) of the cost was non-pharmacologic treatment (namely neurologic 
rehabilitation). The cost of major EC bleeding was 1014 USD/event (48% hospital 
stay cost) and the cost of minor EC bleeding is 49 USD/event (~100% hospital stay 
cost). The cost of acute management of IC bleeding was calculated as 6166 
USD/event (86% hospital stay cost). The annual cost of follow-up of patients with 
IC bleeding was 728 USD/year (52% non-pharmacologic treatment cost). 
CONCLUSIONS: The costs of thromboembolic complications in AF patients are 
quite high. The acute events of stroke or IC bleeding are quite costly, and 
additional costs continue to happen due to treatment of neurologic disabilities 
caused by the primary event. Therefore, the economic burden of these 
thromboembolic events might be well reduced, if the prevention of these events 
could be prevented in AF patients.  
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OBJECTIVES: Venous thromboembolism (VTE), a condition that includes deep 
vein thrombosis (DVT) and pulmonary embolism (PE) is associated with major 
morbidity and mortality and causes huge economic burden. The purpose of this 
study was to evaluate direct and indirect costs of patients with VTE in China, 
producing an average cost per patient per year. METHODS: A cost-of-illness 
analyses was performed. The economic data was collected from an observational 
retrospective study. We recruited 154 patients diagnosed with VTE in Beijing, 
Shanghai and Guangzhou between October 2012 and December2012. Patients or 
their carers completed a questionnaire about resource utilization and 
absenteeism from work in the past year by an interview. Direct medical costs 
included outpatient visit, hospitalization,, ambulatory, drug, diagnostic tests, 
and physiotherapy costs. Indirect costs were estimated using a human capital 
approach. All costs referred to 2011. RESULTS: Among 154 patients, DVT 
accounted for 85.7%,51.95% were female and the mean age was 61.5±12.4. 96.8% 
patients have at least one kind of health insurance. From the societal 
perspective, total costs per patient over 1 year amounted to Chinese Yuan (CNY) 
21484 (median: CNY14039, IQR: CNY6714-CNY32036). The direct medical costs 
were CNY15899 accounting for 74% of the total. The informal care costs were 
CNY3623 accounting for 16.9% of the total. And the indirect costs were CNY1678 
accounting for 7.8%. CONCLUSIONS: The economic burden of VTE in China is 
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OBJECTIVES: Atrial fibrillation (AF) increases the risk of stroke 5-fold and may be 
responsible for larger and more disabling strokes than those without AF which 
increase the associated costs of care. The purpose of this study was to evaluate 
A282 V A L U E  I N  H E A L T H  1 6  ( 2 0 1 3 )  A 1 - A 2 9 8  
  
 
direct and indirect costs of patients with AF-related stroke in China, producing 
an average cost per patient per year and the economic burden of the whole AF-
related stroke Chinese population. METHODS: A cost-of-illness analyses was 
performed. Prevalence data on AF-related stroke for the Chinese population was 
collected from literatures. An observational retrospective study was conducted 
to collect the economic data. We recruited 156 patients diagnosed with AF and 
stroke in Beijing, Shanghai and Guangzhou between October 2012 and December 
2012. Patients or their carers were interviewed about resource utilization and 
absenteeism from work in the past year. Direct medical costs included 
outpatient visit, hospitalization, ambulatory, drug, diagnostic tests, and 
physiotherapy costs. Indirect costs were estimated using a human capital 
approach. All costs referred to 2011. RESULTS: Among 156 patients with AF-
related stroke, 59.35% were male and the mean age was 67.9±30.2 years. 98.0% 
patients have at least one kind of health insurance. From the societal 
perspective, total costs per patient over 1 year amounted to Chinese Yuan (CNY) 
25538 (median: CNY13342, IQR: CNY7662-CNY 38714), with direct costs 
accounting for 94.2% and indirect costs for 5.8% of the total. And for the direct 
costs, the informal care costs were CNY9162. The drug costs were CNY6293. 
Based on the prevalence of AF and AF-related stroke in China from literatures, 
there was about 0.968 million patients of AF-related stroke. Costs for the nation 
are estimated at CNY24.7 billion per year. CONCLUSIONS: The economic burden 
of AF-related stroke in China is considerable. The primary burden on patients 
was due to informal care and drugs.  
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OBJECTIVES: To estimate the costs-of-disease and direct cost components of 
DVT and its consequences including pulmonary thromboembolism (PTE), 
pulmonary hypertension (PH) and post-thrombotic syndrome (PTS), in Turkish 
setting. METHODS: A panel consisting of experts on cardiology, hematology, 
pulmonology and cardiovascular surgery, held a meeting to discuss the disease 
management processes of DVT, PE, PH and PTS. They reviewed the global and 
local literature and guidelines, and also they discussed the spectrum of local 
clinical practices that are performed frequently. All cost components, including 
medications, surgical treatment, hospitalization, out-patient follow-up 
procedures and rehabilitation services were reviewed. September 2012 local 
prices for medications and procedures were used as sources. Mid-2012 USD 
currency rate was used. RESULTS: The cost of acute management of DVT was 
estimated as 253 USD/event. When PE was added, this amount increased to 964 
USD/event (60% of the total cost originated from the hospital stay). The cost of 
PH was studied for acute stage and maintenance health care. The cost of acute 
management of PH was calculated as 1,197 USD. The annual cost of PH was 
estimated as 27,430 USD/year. The sources of 63% and 99.6% of the total cost 
were pharmacologic treatment, for acute stage and maintenance, respectively). 
The costs of PTS, for the first and further years, were 602 USD/year and 543 
USD/year (55% and 60% non-pharmacologic treatment cost, respectively). 
CONCLUSIONS: The cost of DVT is quite low, but when the short-term or long-
term complications are taken into consideration, the economic impact of DVT 
gets well significant. Therefore, the contribution of these conditions should not 
be ignored when modeling the disease management in DVT.  
 
PCV59  
BURDEN OF ILLNESS IN ATRIAL FIBRILLATION IN CHINA  
Zhang L1, Yin C2, Hu SL3 
1Shanghai Centennial Scientific Co. Ltd., Shang Hai, China, 2Johnson & Johnson Medical China, 
ShangHai, China, 3Center for Health Development Research, Shanghai Bureau of Health, School of 
Public Health, Fudan University, Shanghai, China  
OBJECTIVES: Though the burden of illness (BOI) in Atrial Fibrillation (AF) is 
unknown in China, reports from developed countries demonstrated that BOI in 
AF is significant. This study is to analyze the economic burden of AF in China. 
METHODS: A systematic review of studies on AF was conducted in both English 
and Chinese databases from 2000 to 2012. Epidemiologic and economic data 
were abstracted to analyze the two key measures of BOI in AF: the Disability 
Adjusted life Year (DALY) loss in AF and the BOI in stroke attributable to AF. 
RESULTS: The BOI in stroke attributable to AF was RMB 4.9 billion annually of 
which 89% was consumed by the patients above 60. The DALYs loss in AF 
amounts to 4,599,687 in total for the population above 30, which outstrips the 
DALYs loss in hypertensive heart disease (3,348,925) and is very close to the 
DALYs loss in diabetic mellitus (4,769,127). The patients with the age below 60 
contribute to 31% of the total DALYs loss. The DALYs loss in male is more than 
the loss in female (55% vs. 45%). The average DALYs loss increases with age in 
the whole lifetime. Stroke was confirmed as the leading contributor to the DALYs 
loss among AF patients, accounting for 44.21% followed by heart failure (38.14%) 
and myocardial infarctions (17.65%). CONCLUSIONS: The BOI in AF in China is 
considerably significant. Stroke is the driver of BOI in AF in China. The average 
DALYs loss of AF attributable to stroke is higher than the average DALYs loss of 
nonfatal stroke in the US (60-69 years old). As the treatment rate of AF is fairly 
low with little compliance to clinical guidelines, it becomes critical to increase 
the awareness of AF and its appropriate management to restore the sinus 
rhythm and reduce consequent stroke.  
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OBJECTIVES: Heart Failure (HF) represents the most costly condition for the 
Medicare population and one of the most common reasons for admission to US 
Hospitals. This study sought to quantify the actual hospital costs for these 
admissions looking at different diagnoses and varying severities. METHODS: 
Using the Premier hospital database, admissions from year 2010 were included if 
they met the following criteria: (a) one or more inpatient admission(s) with an 
International Classification of Diseases, Ninth Revision (ICD-9) primary diagnosis 
code of HF (both chronic and acute HF) and (b) Diagnosis-Related Group (DRG) 
Codes 291-Complications and Comorbidities, 292-Comorbidities or 293-Without 
any Complications and Comorbidities. Patients with an implantable cardiac 
device (e.g. ICD, CRT-D) were excluded. HF admissions were analyzed by DRG. 
Summary statistics were generated for the cost to the hospital overall and for 
each DRG code. RESULTS: A total of 592,279 inpatient admissions with a HF 
Diagnosis code were initially identified; 483,297 were excluded due to evidence of 
a device and/or a lack of HF-related DRG, leaving 108,982 admissions. Of the 
admissions that met the criteria, 44% were classified as DRG 291, 36% DRG 292, 
and 20% DRG 293. Mean costs were $8184 (SD $8,015; median $6140; first quartile 
(Q1) $3989, third quartile (Q3) $9691). Total costs of an admission were 51% fixed 
and 49% variable. Mean Length-of-Stay for admissions was 4.92 days (SD 4.74; 
median 4.00; Q1 2.00, Q3 6.00). Looking at DRGs separately, DRG 291 had the 
highest mean cost $10,558 (SD $10,033.6), followed by 292 $7,017 (SD $5,728) and 
293 $5,067 (SD $4,091). CONCLUSIONS: The cost of a HF hospitalization typically 
exceeded the average reimbursement provided by Medicare which in 2010 was 
$8245, $5947, and $3917 for DRGs 291, 292, and 293, respectively. Heart Failure is 
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OBJECTIVES: Acute Coronary Syndromes (ACS) often occurs in working-age 
individuals. Limited data exist on the burden of ACS on employees. We 
attempted to determine the total burden of illness, including the direct and 
indirect costs associated with ACS for employees and their dependents. 
METHODS: Medical and pharmacy claims (IMS LifeLink data) along with short 
term disability (STD) and long term disability (LTD) claims (Integrated Benefits 
Institute’s Health and Productivity Benchmarking Database) from 2007-2010 were 
analyzed. Indirect cost analyses consisted of work days lost and wage 
replacement costs for the employers. Direct costs consisted of total all-cause and 
ACS related health costs for those newly diagnosed with ACS in the 12 month 
period following diagnosis. To make direct and indirect costs comparable 
between the two databases, all health care cost estimates were weighted by 
analytic weights derived from age and gender distributions of both datasets. 
RESULTS: A total of 37,340 employees had STD or LTD claims for ACS. The 
majority (77.4%) was male; 94% were less than 65 years of age. Employees with 
ACS had on average 60.2±SE:0.29 STD and 397.9±SE:8.09 LTD days per disability 
incident. For employers, the estimated per claim productivity loss for STD and 
LTD were $7,943±SE:39.7 and $52,473±SE:1,114, respectively. Total annual ACS 
health care costs were $8,170±SE:106. Hospitalizations accounted for 75% of total 
annual ACS health costs. Out of the total number of employees (n=29,100), 36% 
had one or more hospitalizations for ACS. When examining this specific cohort 
of patients hospitalized for ACS, the mean total annual ACS health care costs per 
patient more than doubled ($18,899±SE: 253) CONCLUSIONS: These data 
demonstrate that ACS imposes a substantial economic burden on employees. 
Long term productivity losses and disability costs are significant for employers. 
ACS related hospitalizations represent a large portion of total medical costs.  
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OBJECTIVES: Identify the direct costs in angioplasty patients in private hospitals 
in Brazil. METHODS: It was selected patients from 3 (three) Brazilian states in the 
same operator who underwent angioplasty at private hospitals present in Orizon 
database. Parallely was followed the consumption of these medications during 
the same period by PBM (Pharmaceutical Benefit Management). RESULTS: A total 
of 196 patients were identified in a predominantly male population (76%) and 
above 59 years of age (65%) who underwent angioplasty and subsequently 
consumed drugs via PBM. We found that the average expenditure per patient 
with angioplasty with or without stenting in private hospitals corresponds to 
5579.07 USD, while spending only with prosthesis corresponded to 13% of the 
drive. CONCLUSIONS: The treatment of coronary stenoses does not account only 
